Introduction
============

Over the past 30 years, the reported incidence of thoracic aortic aneurysm (TAA) has increased with better diagnostics and with more patients living to advanced age. Little is known, however, about the true prevalence and mortality rate of TAA in a particular population \[[@R1], [@R2]\]. A population-based study in Rochester, Minnesota reported an age- and gender-adjusted incidence of 5.9 new aneurysms per 100 000 person-years in a Midwestern community over a 30-year period with median ages of 65 years for men and 77 years for women and a distribution of aortic segments as follows: the ascending aorta was involved in 51%, the arch in 11%, and the descending thoracic aorta in 38% \[[@R3], [@R4]\]. The pathogenesis of aortic aneurysms has not been established fully, but it is believed to be multifactorial and include atherosclerosis, increased tissue protease activity, antiprotease deficiency, mechanical factors, inflammatory disorders, infection and genetic collagen defects such as Marfan syndrome and type IV Ehlers-Danlos syndrome. Up to 20% of patients with an aneurysm have a first-degree relative with the same disorder, which suggests a genetic link \[[@R5]\]. The aetiology of TAA is most often aortic dissection in 53%, arteriosclerosis in 29%, aortitis in 8%, cystic medial necrosis in 6%, and syphilis in 4% \[[@R6]\]. The natural history of thoracic aortic aneurysms has not been sufficiently defined. One reason for this is that both the aetiology and location of an aneurysm may affect its rate of growth and propensity for dissection or rupture. The Yale group showed in their longitudinal data that the mean rate of growth for all thoracic aneurysms was significantly lower (0.1 cm/y) than that of abdominal aneurysms (0.2-0.5 cm/y) \[[@R2]\]. The rate of growth, however, was greater for aneurysms of the descending aorta versus the ascending aorta, was greater for dissected versus non-dissected aneurysms, and was most pronounced in Marfan syndrome \[[@R2]\]. Initial size can also be an important predictor of the rate of thoracic aneurysm growth; a study based on 721 patients supported the fact that TAA size had a profound impact on risk for rupture, with an annual rate of 2% in aneurysms \< 5 cm, 3% in aneurysms 5-5.9 cm, and 7% for aneurysms over 6 cm in diameter. Therefore the risk appears to rise abruptly as thoracic aneurysms reach a size of 6 cm \[[@R7], [@R8]\]. In several series aneurysm rupture occurred in 32% to 68% of medically treated patients and rupture accounted for 32% to 47% of deaths; thus the 1-, 3- and 5-year survival rate of thoracic aneurysms left without repair was 65%, 36% and 20%, respectively \[[@R9], [@R10]\]. While most cases of ascending aortic involvement are subject to surgical repair (partially with valve-preserving techniques), aneurysms of the distal arch and descending thoracic aorta are amenable to emerging endovascular techniques as an alternative to classic open repair or to a hybrid approach (combining debranching surgery with stent grafting) in an attempt to improve outcomes.

Endovascular repair
===================

Endovascular treatment of thoracic aortic aneurysms is achieved by transluminal placement of one or more stent-graft devices across the longitudinal extent of the lesion. The prosthesis bridges the aneurismal sac to exclude it from high-pressure aortic blood flow, thereby allowing for sac thrombosis around the stent graft and possible remodelling of the aortic wall (Figure [1](#F1){ref-type="fig"}). Thoracotomy, aortic cross-clamping, left-heart bypass, and single-lung ventilation are all avoided with an endovascular aortic procedure. The use of stent grafts was first reported by Volodos *et al.* in 1986 in a patient with post-traumatic pseudoaneurysm of the thoracic aorta \[[@R11]\]. With technology proceeding at a fast pace, both custom-designed and commercially available stent grafts are available for treating thoracic aortic disease (Figure [2](#F2){ref-type="fig"}). By now, several institutions have substantiated both the safety and the effectiveness of stent grafts for the repair of thoracic aortic aneurysms \[[@R12]-[@R14]\]. With increasing endovascular experience numerous other aortic diseases, such as aortic dissection, penetrating atherosclerotic ulcers, aortopulmonary fistulas, acute aortic rupture from blunt chest trauma, and mycotic aneurysms, have been investigated as a potential indication for endovascular treatment.

![(**A**) CT angiogram showing a circumscript aneurysm of the descending thoracic aorta in a middle-aged male patient selected for endografting. (**B**) 1-year follow-up after successful endovascular exclusion of the aneurysm by stent-graft placement demonstrates marked shrinkage of periprosthetic aneurysm and optimal wall apposition of the stent graft](AMS-6-5-646_F1){#F1}

![A selection of thoracic stent grafts currently available for endoluminal repair. Zenith TX2 by Cook Medical(**A**), TAG by GORE (**B**); Valiant by Medtronic AVE (**C**); Relay Thoracic Stent-Graft by Bolton Medical (**D**); EndoFit by LeMaitre Vascular (**E**)](AMS-6-5-646_F2){#F2}

Technique
=========

Currently, there is ongoing controversy over which patients should be treated by endovascular means (Table [I](#TI){ref-type="table"}). The long-term durability of aortic stent grafts is not yet known, and therefore cautious patient selection is advocated. The suitability of a given patient for endovascular repair is based on both clinical and anatomical considerations. At present, stent grafts are routinely used to treat patients with thoracic aneurysms distal to the aortic arch. Inoue *et al*. have performed aortic arch reconstructions using transluminally placed endovascular branched stent grafts to treat aneurysms involving the aortic arch. This concept, however, was a failure, with many complications, and was not embraced in the community. Successful TAA exclusion requires normal segments of native aorta at both ends of the lesion of at least 15 mm to 25 mm to ensure adequate launching and contact between the stent graft and the aortic wall with a tight circumferential seal. Devices are oversized by 10% in diameter to provide sufficient radial force for adequate fixation \[[@R15]\]. The preferred and most common site (41-58%) of vascular access is the common femoral artery \[[@R16], [@R17]\]. Less frequently, access to the iliac artery (9-44%) via an extra-peritoneal approach is required. Retroperitoneal exposure to the abdominal aorta is necessary in 14-30% of cases, especially in small, elderly women \[[@R16], [@R17]\]. In patients with multiple aortic aneurysms involving both the thoracic and abdominal aorta a combination of conventional abdominal aortic replacement with endovascular stent-graft placement into the thoracic aorta under fluoroscopic guidance is feasible \[[@R18]\]. Care must be taken not to occlude major arterial branches or to bypass them prior to stent-graft placement. A rational approach to endovascular treatment of aortic aneurysms with a short proximal neck is transposition of the left subclavian artery prior to stent-graft placement. After deployment short inflation of a latex balloon should be performed to improve apposition of the stent struts to the aortic wall. Post-procedurally, both Doppler-ultrasound and contrast fluoroscopy should be performed to document the immediate result. After removing the sheath and guide wire the access sites can be closed in standard surgical fashion.

###### 

Current indications for endovascular treatment of thoracic aortic disease

  ---------------------------------------------------------------------------------------
   **Disease etiology**
    Aortic aneurysms
     Atherosclerotic/degenerative
     Posttraumatic
     Mycotic
     Anastomotic
     Cystic medial necrosis
     Aortitis
    Stanford type B aortic dissection
     Acute
     Chronic
    Giant penetrating ulcer
    Traumatic aortic tear
    Aortopulmonary fistula
    Marfan syndrome
   **Aneurysm morphology**
   Aneurysm of the descending aorta
     Proximal neck length = 2cm
     \< 2cm if supra-aortic vessels have been transposed prior to stent-graft placement
     Distal neck length = 2cm
     Diameter \> 6cm
   **Patients condition**
   Preferentially older age
   Unfit for open surgical repair or high-risk patients
     Chronic obstructive pulmonary disease
     Severe coronary heart disease
     Severe carotid artery disease
     Renal insufficiency
   **Suitable vascular access site**
   **Life expectancy of more than 6 months**
  ---------------------------------------------------------------------------------------

Hybrid procedures for aortic arch pathologies
=============================================

The aortic arch morphology is challenging because of angulations and the proximity of the supra-aortic branches, which need to be preserved. Traditional open arch reconstruction using hypothermic cardiac arrest, extracorporeal circulation and selective cerebral perfusion has been demonstrated to effectively manage aortic arch pathologies. However, this current standard procedure for any arch pathology carries significant mortality (2-9%) and risk of paraplegia and cerebral stroke in 4-13% of cases \[[@R19]\]. Therefore, open repair is often reserved for low-risk patients. Hybrid arch procedures (HAP) are a combination of debranching bypass (supra-aortic vessel transposition) to establish cerebral perfusion and subsequent thoracic endografting to provide patient-centred solutions for complex aortic arch lesions (Figure [3](#F3){ref-type="fig"}). HAP is performed without hypothermic circulatory arrest and extracorporeal circulation and could expand the treatment group to older patients with severe comorbidities and redo-surgery currently ineligible for open surgical intervention. There are two different hybrid approaches with either extra-anatomic or intrathoracic supra-aortic vessel transposition. To treat distal arch aneurysms involving both the left subclavian and the left common carotid artery, those vessels can be translocated upstream to the right common carotid artery approached via cervical access (hemi-arch debranching) \[[@R20]\]. For arch aneurysms extending to the innominate artery the ascending aorta can be used, via sternotomy, as a donor site to revascularize all three supra-aortic arteries (total arch debranching). The key to success is the quality of the unimpaired ascending aorta as a donor site for the debranching bypass and proximal landing zone for the stent grafts.

![Contrast-medium enhanced MR angiography of the aorta in a case of aortic arch aneurysm. **A**-- aneurysm of the aortic arch involving the supra-aortic branches. **B**-- post-interventional/-surgical result after hybrid procedure with debranching of the supra-aortic vessels and stent-graft implantation in the aortic arch](AMS-6-5-646_F3){#F3}

Follow-up
=========

When a thoracic aortic aneurysm is first detected its growth rate is not known yet. It is therefore appropriate to obtain a repeated imaging study 6 months after the initial study. If the aneurysm is unchanged in size, it is then reasonable to obtain an imaging study on an annual basis in most cases. In non-Marfan patients and in the absence of acute aortitis, thoracic aortic aneurysms tend to grow slowly and annual imaging is sufficient for surveillance. However, should there be a significant increase in aortic size per year (\> 0.5 cm per year), action is required or at least shorter imaging follow-up. Follow-up examinations should be performed at discharge, 6 and 12 months and annually thereafter. Imaging studies include helical CT and 3D reconstruction, or if endotension is suspected, MR angiography is the preferred method of evaluation.

Results from the literature
===========================

Primary technical success was generally defined as complete exclusion of the TAA, stent-graft patency, and restoration of normal blood flow immediately after endovascular repair (EVR). Secondary technical success was defined as complete TAA exclusion, graft patency, and restoration of blood flow within 30 days of stent-graft placement. Several studies have reported high success rates with 85% to 100% of procedures in successful deployment and functional exclusion of the aneurysm. Major complications occurred in 14-18% of patients depending on the acuity at presentation, with very low incidence of paraplegia. In the recent literature, different groups had periprocedural stroke rates of 0% to 7% \[[@R17], [@R21]\] and incidence rates for paraplegia between 0% and 5% \[[@R17], [@R21]-[@R23]\]. Although low, these rates remain significant, especially because it is impossible to re-implant intercostal arteries in this setting. Endoleak is the Achilles heel of endovascular stent-graft procedures. The rate of endoleak immediately after TAA stent-graft placement has been reported to be between 4% and 24% \[[@R23], [@R24]\].

Early and late mortality rate ranged from 0 to 14% and is usually attributable to the preoperative status of the patients. Most studies showed a patient survival rate of 70-80% at 1, 3 and 5 years. (Table [II](#TII){ref-type="table"}) \[[@R17], [@R21]-[@R47]\]. Data from 457 patients treated with stent grafts and collected in a registry (113 emergency and 344 elective cases) revealed that among 422 patients who survived the interventional procedure (in-hospital mortality 5%), mortality during follow-up was 8.5% (36 patients), of which 11 patients had died from the aortic disease; persistent endoleak was reported in 64 cases, of which 44 were primary (9.6%) and 21 occurred during follow-up (4.9%) \[[@R25]\]. Kaplan-Meier overall survival estimate at 1, 3 and 5 years was 90.9%, 85.4% and 77.5%. At the same intervals, freedom from a second procedure (either open conversion or endovascular) was 92.5%, 81.3%, and 70.0%, respectively \[[@R25]\]. At Stanford University first-generation thoracic aortic grafting was performed in 103 patients from 1992 to 1997. Of these patients, 60% were deemed unsuitable for open standard aortic replacement \[[@R26]\]. The average diameter of the aneurysms was 6 cm (range 4-11 cm), and the length varied from 1 cm in post-traumatic aneurysm to 22 cm. In 8 patients a preoperative subclavian-to-carotid bypass or transposition was performed to allow the orifice of the subclavian artery to be covered with the stent graft without obstructing flow to the arm. The mortality rate in this pioneering study was 9%, with a 3% incidence of paraplegia. Complete exclusion of the aneurysm occurred in 84% of patients and endoleaks were observed in 25 patients (24%); these were subsequently successfully treated in 11 patients by a combination of overstenting and coiling. The survival rate was 81% at 1 year and 73% at 2 years. Late rupture occurred in 2% of patients at 22-month average follow-up \[[@R26]\]. A 6-year prospective case series involving 84 patients was completed by Ellozy *et al.* \[[@R29]\]. Primary technical success was achieved in 90%, and successful exclusion of the aneurysm was achieved in 82%. However, major procedure-related or device-related complications occurred in 38%, including proximal attachment failure (8%), distal attachment failure (6%), mechanical device failure (3%), periprocedural death (6%), and late aneurysm rupture (6%). More encouraging was the fact that only 3% suffered persistent neurological complications \[[@R29]\].

###### 

Overview of published data regarding endovascular treatment of thoracic aortic aneurysm

  --------------------------------- ----- --------------------- -------------------------- ------------------------ ------------------ ---------------- -------------------------- -----------------------------------
  Author, year                      *N*   Follow-up \[month\]   Technical success \[%\])   30-Day Mortality \[%\]   Paraplegia \[%\]   Endoleak \[%\]   Long-Term Survival \[%\]   Devices
  Dake, 1998 \[[@R17]\]             103   22                    83                         9                        3                  24               73 (2 years)               Homemade
  Ehrlich, 1998 \[[@R23]\]          10    NA                    80                         10                       0                  20               NA                         Talent
  Cartes-Zumelzu, 2000 \[[@R24]\]   32    16                    90.6                       9.4                      3.1                15.4             90.2 (32 months)           Excluder, Talent
  Grabenwoger, 2000 \[[@R30]\]      21    NA                    100                        9.5                      0                  14.3             NA                         Talent, Prograft
  Najibi, 2002 \[[@R31]\]           24    12                    94.7                       5.3                      0                  0                89.5 (1 year)              Excluder, Talent
  Heijmen, 2002 \[[@R32]\]          28    21                    96,4                       0                        0                  28.6             96.4 (21 months)           Talent, Excluder
  Schoder, 2003 \[[@R33]\]          28    22.7                  100                        0                        0                  25               80.2 (3 years)             Excluder
  Bell, 2003 \[[@R34]\]             67    17                    NA                         2                        4                  4.8              89 (1 year)                Gore, Talent
  Lepore, 2003 \[[@R35]\]           21    12                    100                        9.5                      4.8                19               76.2 (1 year)              Excluder, Talent
  Ouriel, 2003 \[[@R36]\]           31    6                     NA                         12.9                     6.5                32.3             81.6 (6 months)            Excluder, Talent
  Czerny, 2004 \[[@R37]\]           54    38                    94.4                       9.3                      0                  27.8             63 (3 years)               Excluder, Talent
  Makaroun, 2004 \[[@R38]\]         142   29.6                  97.9                       1.5                      3.5                8.8              75 (2 years)               TAG
  Leurs, 2004 \[[@R39]\]            249   32                    87                         10.4                     4                  4.2              80.1 (1 year)              Excluder, Talent, Zenith, Endofit
  Glade, 2005 \[[@R40]\]            42    15                    NA                         NA                       2                  NA               NA                         Gore, Talent
  Greenberg, 2005 \[[@R41]\]        100   14                    NA                         NA                       1                  6                83 (1 year)                Zenith
  Riesenmann, 2005 \[[@R42]\]       50    9                     96                         NA                       0                  10               79.4 (1 year)              Talent
  Ricco, 2006 \[[@R43]\]            166   NA                    NA                         5                        3.6                16.2             NA                         Gore, Talent
  Wheatley, 2006 \[[@R44]\]         156   21.5                  98.7                       3.8                      0.6                11.5             76.6 (1 year)              Gore
  Bavaria, 2007 \[[@R45]\]          140   24                    98                         2.1                      2.9                10               NA                         Gore
  Qu, 2008 \[[@R46]\]               46    15.2                  100                        9.2                      3.4                5.8              88.5 (2 years)             EndoFit
  Ting, 2009 \[[@R47]\]             24    21                    98                         NA                       0                  NA               75 (2 years)               AneuRx, Talent, Zenith, Excluder
  --------------------------------- ----- --------------------- -------------------------- ------------------------ ------------------ ---------------- -------------------------- -----------------------------------

For aneurysm disease encompassing the descending thoracic aorta and in selected cases the distal aortic arch, use of endovascular stent grafts for repair of suitable anatomical conditions is a promising, non-surgical alternative; however, morphology and graft sizing are paramount in case selection.
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